Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | HPGD | P15428 | 4/20 | 0.96 |
| ▸ | GLA | P06280 | 4/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.96 |
| ▸ | GAA | P10253 | 3/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL1652921 | 0.99 | KDM4E (0.95) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5424458 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL30684952 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL6528 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41546 | 0.98 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL8057933 | 0.97 | KDM4E (0.98) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL41545 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5427410 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL31284920 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 | |
| Terazosin SCHEMBL5525882 | 0.97 | KDM4E (1.00) | KDM4EALDH1A1HPGDGLAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3826640-A2 | COMPOSITION CONTAINING BECLOMETHASONE FOR THE PREVENTION AND THE TREATMENT OF BACTERIAL PROSTATITIS AND VAGINITIS | SOFAR S.p.A. (IT) | 2021-06-02 | — | — | EP | disclosed |
| CN-112543638-A | Composition containing beclomethasone for preventing and treating bacterial prostatitis and vaginitis | 索法尔公司 | 2021-03-23 | — | — | CN | disclosed |
| WO-2020021509-A2 | COMPOSITION CONTAINING BECLOMETHASONE FOR THE PREVENTION AND THE TREATMENT OF BACTERIAL PROSTATITIS AND VAGINITIS | SOFAR S.P.A. (IT) | 2020-01-30 | — | — | WO | disclosed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | disclosed |
| US-9089522-B2 | Method of reducing total cholesterol level by administering matrilin-2 polypeptide | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| CN-101668769-B | Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors | AETERNA ZENTARIS GMBH | 2014-07-02 | — | — | CN | disclosed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8598320-B2 | Anti-PCSK9 and methods for treating lipid and cholesterol disorders | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1967202-A1 | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity | AEterna Zentaris GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| CN-101065501-A | Method for determining genotoxicity | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | CN | disclosed |
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060110768-A1 | Method for determining genotoxicity | ROCHE PALO ALTO LLC | 2006-05-25 | — | — | US | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | ADRA1D 651/4885ADRA1A 434/4885ADRA1B 364/4885 |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | PCSK9, PCSK7, CETP | ADRA1D 3634/4885ADRA1A 3522/4885ADRA1B 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.